CommercialAdministrativeLow impact
06.02.14i, In Vitro Chemosensitivity and Chemoresistance Assays
Independence Blue Cross·Oncology, Pathology·Medical Policy
We identified it
Jun 25, 2026
Summary
Independence Blue Cross reissued policy 06.02.14i on 06/24/2026 with no substantive changes. The policy maintains that in vitro chemosensitivity and chemoresistance assays remain experimental/investigational and are not covered. CPT codes 81535, 81536, and 0564T, along with procedure code 81536, are documented as representing covered test types, but coverage denial applies to all diagnoses.
Action Required
No immediate action required. This is a routine annual policy reissuance with no coverage changes. Billing team should verify that claims for CPT codes 81535, 81536, 0564T, and 89240 continue to be denied as experimental/investigational per existing procedures. No workflow updates or system changes are needed at this time. Maintain current denial protocols for all in vitro chemosensitivity and chemoresistance assay claims submitted under Independence Blue Cross commercial plans.